Literature DB >> 10174322

Measuring sensitivity in pharmacoeconomic studies. An integration of point-sensitivity and range-sensitivity.

M J Nuijten1, M Hardens.   

Abstract

The level of uncertainty with regard to the outcomes of pharmacoeconomic studies cannot be completely covered by the statistical methods routinely employed to handle uncertainty in clinical research. Sensitivity analysis is the most common methodology to deal with the extra uncertainty associated with pharmacoeconomics, and has also been incorporated in recent guidelines on healthcare evaluation. However, the execution of a sensitivity analysis and the interpretation of its results have not yet been standardised, which may lead to subjectivity and consequently weaken the value of economic evaluations. This article presents a method of dealing more systematically with uncertainty and eliminating potential bias in sensitivity analysis, with regard to the measurement of sensitivity and the comparison of the degree of sensitivity between variables. An assessment of the disadvantages of using slope as a measure of sensitivity leads to 2 types of sensitivity analyses (point-sensitivity and range-sensitivity), which are integrated into one method for the measurement of sensitivity.

Mesh:

Year:  1997        PMID: 10174322     DOI: 10.2165/00019053-199712050-00006

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  7 in total

1.  Cost-effectiveness and cost-benefit analyses in the medical literature. Are the methods being used correctly?

Authors:  I S Udvarhelyi; G A Colditz; A Rai; A M Epstein
Journal:  Ann Intern Med       Date:  1992-02-01       Impact factor: 25.391

2.  Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada.

Authors:  A S Detsky
Journal:  Pharmacoeconomics       Date:  1993-05       Impact factor: 4.981

3.  Canadian guidelines for economic evaluation of pharmaceuticals. Canadian Collaborative Workshop for Pharmacoeconomics.

Authors:  G W Torrance; D Blaker; A Detsky; W Kennedy; F Schubert; D Menon; P Tugwell; R Konchak; E Hubbard; T Firestone
Journal:  Pharmacoeconomics       Date:  1996-06       Impact factor: 4.981

4.  Probabilistic sensitivity analysis methods for general decision models.

Authors:  G C Critchfield; K E Willard; D P Connelly
Journal:  Comput Biomed Res       Date:  1986-06

5.  A Markov process analysis comparing the cost effectiveness of maintenance therapy with citalopram versus standard therapy in major depression.

Authors:  M J Nuijten; M Hardens; E Souêtre
Journal:  Pharmacoeconomics       Date:  1995-08       Impact factor: 4.981

6.  Economic analysis of health care technology. A report on principles. Task Force on Principles for Economic Analysis of Health Care Technology.

Authors: 
Journal:  Ann Intern Med       Date:  1995-07-01       Impact factor: 25.391

7.  Report from the Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Guidelines for economic evaluation of pharmaceuticals: Canada.

Authors: 
Journal:  Int J Technol Assess Health Care       Date:  1995       Impact factor: 2.188

  7 in total
  3 in total

1.  Pricing matrix model: dealing with uncertainty.

Authors:  Mark J C Nuijten
Journal:  Eur J Health Econ       Date:  2007-01-13

2.  Measuring sensitivity in pharmacoeconomic studies. Refining point sensitivity and range sensitivity by incorporating probability distributions.

Authors:  M J Nuijten
Journal:  Pharmacoeconomics       Date:  1999-07       Impact factor: 4.981

3.  Dermatan sulfate versus unfractionated heparin for the prevention of venous thromboembolism in patients undergoing surgery for cancer. A cost-effectiveness analysis.

Authors:  E Attanasio; P Russo; G Carunchio; L Caprino
Journal:  Pharmacoeconomics       Date:  2001-01       Impact factor: 4.981

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.